- Diet Drugs Get a New Slim Chance at Approval
Contrave, the investigational diet pill combination of naltrexone and bupropion, has been granted a possible new lease on life by the FDA. In January of this year the FDA issued a complete response letter to Orexigen, the drug's sponsor. Now Orexigen says that it has received guidance from the FDA that could lead to approval of the drug in 2014. Contrave、ナルトレキソンおよびブプロピオンの治験食事療法の丸薬の組み合わせは、FDAによって生活上で可能な限り新しいリースを付与されています
- Merkel party pays price of stance on nuclear power
Chancellor Angela Merkel's conservatives were ousted from power in Germany's richest state for the first time in 58 years, humiliated by the environmentalist Greens in a regional election whose outcome raised doubts about her political... メルケル首相の保守派は、その結果彼女の政治的な疑問を提起地方選挙で環境保護グリーンズで屈辱58年で初めて、ドイツの豊かな状態の権力の座から追放された...
- TTOP-AF Trial Demonstrates Efficacy of RF Ablation System, But Fails To Prove Safety
A new trial demonstrates that an investigational RF ablation system is more effective than medical management in treating persistent AF, but the trial failed to meet a key predefined safety goal. 新しい試験は、治験のRFア。。u200b。。u200bブレーションシステムは永続的な心房細動の治療における医学的管理よりも効果的であることを示しますが、試験では、キー定義済みの安全目標を満たすことができなかった
- GameStop's Big Buyback
After hours: Incyte shares rise on positive drug trial results; CLARCOR beats Street. 時間後：インサイト社の株式は、正の治験結果に上昇
|
